Trial · NCT00072358
Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma
NCT00072358, Phase 2, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2022-05-16
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma. Trials, record NCT00072358. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00072358
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma
- NCT number
- NCT00072358
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 291 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Neuroblastoma
- Interventions
- anti-GD2 murine IgG3 monoclonal antibody 3F8, anti-GD2 murine IgG3 monoclonal antibody 3F8
- First posted
- 2003-11-06
- Last updated
- 2022-05-16
- Results first posted
- 2022-05-16
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Efficacy at Completion of Treatment | 3 years | |
| Primary | Relapse-free Survival Every 3 Months | 3 years | |
| Secondary | Compare Granulocyte Activation in Patients Treated With Short-term vs Prolonged Daily Exposure to Sargramostim (GM-CSF) After 4 Courses | 3 years | |
| Secondary | Simplify Treatment With Consequent Reduction in Cost | 3 years |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Efficacy at Completion of Treatment | 3 years | Data were not collected | ||
| PRIMARY | Relapse-free Survival Every 3 Months | 3 years | Data were not collected | ||
| SECONDARY | Compare Granulocyte Activation in Patients Treated With Short-term vs Prolonged Daily Exposure to Sargramostim (GM-CSF) After 4 Courses | 3 years | Data were not collected | ||
| SECONDARY | Simplify Treatment With Consequent Reduction in Cost | 3 years | Data were not collected |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Participants With Refractory Bone Marrow Disease and High Risk of Recurrence | 291 | |
| Overall Study | COMPLETED | Participants With Refractory Bone Marrow Disease and High Risk of Recurrence | 291 | |
| Overall Study | NOT COMPLETED | Participants With Refractory Bone Marrow Disease and High Risk of Recurrence | 0 |
Source ClinicalTrials.gov
Adverse events84
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Pain, other | General disorders | Participants With Refractory Bone Marrow Disease and High Risk of Recurrence | 157 | 291 | |
| other | Urticaria | Skin and subcutaneous tissue disorders | Participants With Refractory Bone Marrow Disease and High Risk of Recurrence | 142 | 291 | |
| other | Flushing | Vascular disorders | Participants With Refractory Bone Marrow Disease and High Risk of Recurrence | 103 | 291 | |
| other | Pruritus | Skin and subcutaneous tissue disorders | Participants With Refractory Bone Marrow Disease and High Risk of Recurrence | 100 | 291 | |
| other | Vomiting | Gastrointestinal disorders | Participants With Refractory Bone Marrow Disease and High Risk of Recurrence | 90 | 291 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Participants With Refractory Bone Marrow Disease and High Risk of Recurrence | 80 | 291 | |
| other | Nausea | Gastrointestinal disorders | Participants With Refractory Bone Marrow Disease and High Risk of Recurrence | 78 | 291 | |
| other | Fever | General disorders | Participants With Refractory Bone Marrow Disease and High Risk of Recurrence | 63 | 291 | |
| other | Edema | General disorders | Participants With Refractory Bone Marrow Disease and High Risk of Recurrence | 58 | 291 | |
| other | Dry skin | Skin and subcutaneous tissue disorders | Participants With Refractory Bone Marrow Disease and High Risk of Recurrence | 53 | 291 |
1 to 10 of 84Source ClinicalTrials.gov
See all 84 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Participants With Refractory Bone Marrow Disease and High Risk of Recurrence | 135 | 291 |
| Total, other adverse events | Participants With Refractory Bone Marrow Disease and High Risk of Recurrence | 287 | 291 |
| Total, serious adverse events | Participants With Refractory Bone Marrow Disease and High Risk of Recurrence | 153 | 291 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00072358
GET https://conductscience.org/api/trials/v1/NCT00072358/events?page=2